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OBJECTIVE: Diabetic retinopathy (DR) is associated with hyperglycemia-driven microvascular pathology and neuronal compromise
in the retina. However, DR is also linked to dyslipidemia. As omega-3 (o-3) polyunsaturated fatty acids (PUFAs) are protective in
proliferative retinopathy, we investigated the capacity of o-3PUFAs to preserve retinal function in a mouse model of type 2
diabetes mellitus (T2DM).
DESIGN: Male leptin-receptor-deﬁcient (db/db) mice were maintained for 22 weeks (4 weeks–26 weeks of life) on calorically and
compositionally matched diets, except for 2% enrichment in either o-3 or o-6PUFAs. Visual function was assessed at 9, 14 and 26
weeks by electroretinography. Retinal capillary and neuronal integrity, as well as glucose challenge responses, were assessed on
each diet.
RESULTS: The o-3PUFA diet signiﬁcantly preserved retinal function in the mouse model of T2DM to levels similar to those observed
in nondiabetic control mice on normal chow. Conversely, retinal function gradually deteriorated in db/db mice on a o-6PUFA-rich
diet. There was also an enhanced ability of o-3PUFA-fed mice to respond to glucose challenge. The protection of visual function
appeared to be independent of cytoprotective or anti-inﬂammatory effects of o-3PUFAs.
CONCLUSION: This study identiﬁes beneﬁcial effects of dietary o-3PUFAs on visual function in T2DM. The data are consistent with
dyslipidemia negatively impacting retinal function. As o-3PUFA lipid dietary interventions are readily available, safe and
inexpensive, increasing o-3PUFA intake in diabetic patients may slow the progression of vision loss in T2DM.
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INTRODUCTION
Diabetic retinopathy (DR) is a major complication of diabetes and
the most frequent cause of blindness in ages 30–60 years.
1 The
number of patients with diabetes worldwide is projected to be
366 million by 2030,
2 with type 2 diabetes mellitus (T2DM)
accounting for the greatest increase in new cases. It is estimated
that over 80% of patients afﬂicted with T2DM will develop a form
of DR within 20 years of diagnosis.
3 Clinically, DR is ﬁrst seen as a
progressive loss of retinal vasculature (nonproliferative DR)
characterized by microaneurysms, pericyte loss and basement
membrane thickening.
4 Importantly, often preceding vascular
changes, retinal neurons, including retinal ganglion cells (RGCs),
are damaged.
5–7 Nonproliferative DR is also associated with
increased inﬂammation, increased vascular permeability and
leukostasis. In response to retinal hypoxia resulting from the
vessel loss in nonproliferative DR,
8 there is a second phase
consisting of pathological vasoproliferation (proliferative DR),
which can cause tractional retinal detachment leading to
blindness.
Besides hyperglycemia, dysregulation of lipid metabolism is
associated with DR. Modulating a patient’s lipid proﬁle
9–11 can
improve DR. Lipids have important regulatory roles beyond
energy storage and membrane structure. Importantly, intake of
essential omega-3 (o-3) long-chain polyunsaturated fatty acids
(PUFAs) directly inﬂuences lipid signaling and has therapeutic
potential in metabolic and inﬂammatory conditions.
12,13 As
mammals are not readily capable of synthesizing o-3 and
o-6PUFAs, the content of these PUFAs in tissue is almost solely
deﬁned via dietary intake.
In a mouse model of oxygen-induced retinopathy with
characteristics of proliferative DR, we have previously demon-
strated that a diet enriched in o-3PUFAs (similar to human
Japanese diets) effectively reduces pathological retinal neovascu-
larization when compared with an o-6PUFA-rich diet (mimicking
human American diets).
14–16
These ﬁndings are consistent with the human Age-Related Eye
Disease Study reports, which found that total dietary intake of
o-3PUFAs is inversely associated with the risk of neovascular age-
related macular degeneration.
17 Moreover, a lower incidence of
T2DM has been reported in individuals whose diets are rich in
o-3PUFAs.
18
Although tight glycemic control retards retinopathy, compli-
ance is difﬁcult. A safe nutritional intervention to help prevent DR
would answer a clinically unmet need. Here we present the ﬁrst
evidence that dietary o-3PUFA supplementation reduces hyper-
glycemia, improves glucose tolerance and directly preserves
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MATERIALS AND METHODS
Animals
All studies adhered to the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthalmic and
Vision Research, and were approved by Children’s Hospital Boston Animal
Care and Use Committee. Institutional Animal Care and Use Committee
(IAACUC) protocol number 10-08-1770R. Male db/db mice and nondiabetic
heterozygous littermate controls (BKS.Cg-Dock7
mþ/þ Lepr
db/J, stock
number 000642) we from The Jackson Laboratories (Bar Harbor, ME, USA).
Omega-3, o-6PUFA diets and control chow
Mice were fed from 4 weeks to 26 weeks with deﬁned rodent diets.
14–16
These calorically matched rodent diets contained either 2% o-3PUFAs
(DHA and EPA) for the treatment group or 2% o-6PUFAs (arachidonic acid)
for the control group. Dietary PUFAs were produced by DSM Nutritional
Products (Parsippany, NJ, USA) under the trade name ROPUFA. The
arachidonic acid and DHA supplements, under the trade names ARASCO
and DHASCO, respectively, were obtained from Martek Biosciences Corp.
(Columbia, MD, USA). Standard rodent chow (‘normal feed’) from Purina
(Framingham, MA, USA) was used as a control diet in db/þ control mice
for all retinal electrophysiology experiments.
Blood glucose measurements and glucose tolerance test
Body weight and baseline fasting blood glucose levels (Accu-Chek, Roche,
Indianapolis, IN, USA) of the mice were recorded. Glucose tolerance tests
(age 7 weeks) consisted of blood glucose measurement, then injection of
1ml 10% D-glucose intraperitoneally, followed by blood glucose measure-
ments at 30, 60 and 240min.
Electroretinography
Retinal function was assessed
19 at 9, 14 and 26 weeks by full-ﬁeld
electroretinography (ERG) in db/db mice fed o-3- or o-6PUFA chows,
and in heterozygous mice on normal chow. The stimuli were ‘green’ light-
emitting diode ﬂashes of doubling intensity from B0.0005 to
B2.05cdsm
 2 and then ‘white’ xenon-arc ﬂashes–half as efﬁcient
(per cdsm
 2) at eliciting a b-wave
19–from B8.2 to B1.050cdsm
 2, all
presented to the dark-adapted, cycloplegic eye. The response to a
1.024cdsm
 2 green light ﬂickering at 8Hz in the presence of an amber
background that suppressed the saturating rod photoresponse by 490%
was recorded.
The saturating photoresponse was characterized from the ERG by
optimization of the free parameters of the Hood and Birch
20 formulation of
the Lamb and Pugh
21 model of the activation of phototransduction:
P3 i;t ðÞ ¼ RmP3
  1  exp  1/2   i   S   t  td ðÞ
2
 
fortd ot o15ms: ð1Þ
In this model, i is the intensity of the ﬂash (cdsm
 2), t is elapsed time (s),
RmP3 (mV) is proportional to the magnitude of the dark current,
S (cd
 1s
 3m
2) summarizes the kinetics of phototransduction and td is
a brief delay (s).
The postreceptor response, P2, mostly from bipolar cells,
22,23 was
obtained by digitally subtracting P3 (equation (1)) from the intact ERG.
The response versus intensity relationship of P2 was ﬁt to the Naka-
Rushton equation,
P2 i ðÞ
RmP2
¼
i
iþkP2
; ð2Þ
wherein P2(i) is the amplitude (mV) of the response to a stimulus of i
intensity, RmP2 (mV) is the saturating bipolar response and kP2 is the ﬂash
intensity that elicits a half-maximum P2; kP2
 1 and S are suprathreshold
measures of sensitivity. However, P2 increases in linear proportion to
stimulus intensity over a narrow range of dim ﬂash intensities,
23 and thus
the sensitivity of P2 at threshold was deﬁned in this range
24 by scaling the
amplitude of each P2 by the intensity used to elicit it and ﬁtting
Sf i ðÞ
Sm
¼
i 1
i 1 þF 1
1/2
ð3Þ
to the resulting sensitivities. Sf(i) is the fractional sensitivity
(mVcd
 1s
 1m
2) of the P2 response to a ﬂash of i intensity, Sm is the
sensitivity of the retina at threshold and F1/2 is the stimulus intensity at
which sensitivity has fallen by half.
The oscillatory potentials (OPs) characterize activity in retinal cells
distinct from those that generate P3 and P2. The OPs were analyzed in the
frequency domain following discrete Fourier transform of the ﬁrst 128ms
of P2.
25 The saturating energy in the OPs, Em (pJ), was derived similarly to
RmP2 from the response versus intensity relationship of OP energy. Em is
related to the square of OP amplitude,
25 and thus its root (Em
1/2) was used
in all analyses.
To evaluate a cone-mediated response, the trough-to-peak amplitude of
the light-adapted, 8Hz ﬂicker response (R8) was measured.
Isolation of retinal vasculature
Enucleated eyes from 26-week-old db/db mice were ﬁxed in formalin.
Retinal vasculature was isolated by trypsin digest,
26,27 then dried on
microscope slides and stained with hematoxylin–periodic acid Schiff.
Acellular capillaries were counted (masked)
28 and expressed per mm
2 of
the retina.
Retinal ﬂatmount and RGC imaging
Ganglion cells were quantiﬁed in both central and peripheral regions of the
retina in a masked fashion in 26-week-old db/db mouse retinas ﬁxed
in 4% paraformaldehyde, stained with b-III tubulin primary antibody
(C terminus, TP1691, ECM Biosciences,V e r s a i l l e s ,K Y ,U S A ) ,a n dt h e nw h o l e -
mounted with the photoreceptor side down and embedded in SlowFade
Antifade reagent (Invitrogen, Grand Island, NY, USA). Flatmounts were visualized
and recorded with  63 objectives on a Leica TCS SP2 Confocal microscope
and Leica Confocal Software (Leica Microsystems, Buffalo Grove, IL, USA).
RNA isolation and reverse-transcription quantitative PCR
Retinas were isolated, treated with DNase I (Qiagen, Valencia, CA, USA), and
then the RNA was isolated and converted into cDNA with reverse
transcriptase (Invitrogen). PCR primers targeting tumor necrosis factor-a,
interleukin (IL)-1b, IL-6, IL-10, intercellular adhesion molecule-1, claudin-5,
plasmalemma vesicle-associated protein, b-III tubulin and control cyclo-
philin A were designed with Primer Bank and NCBI Primer Blast software.
Quantitative analysis of gene expression was quantiﬁed with an ABI Prism
7700 and SYBRGreen Master Mix kit (Applied Biosystems, Foster City, CA,
USA), and expressed relative to cyclophilin A.
Enzyme-linked immunosorbent assay measurements of
inﬂammatory proﬁles
Serum was collected from mice at 26 weeks of age and analyzed for the
presence of inﬂammatory proteins using the Multiplex-ELISA (5P30 DK 36836
Specialized Assay Core) at the Joslin Diabetes Center (Boston, MA, USA).
Statistics
ERG parameters were expressed as log values so that changes of ﬁxed
proportion became linear, and were normalized to the values obtained at
each age in the heterozygous mice with normal chow so that confounding
effects of the natural aging process were eliminated. Differences in ERG
parameters were detected by analysis of variance followed by Tukey’s
honestly signiﬁcant difference test. Statistical testing of anatomic and
molecular biological results was limited to o-3 and o-6PUFA mice, and
performed by two-sample t-test, unless otherwise indicated.
RESULTS
Dietary intake of o-3PUFAs preserves visual function in type 2
diabetes
The development of DR is associated with progressive loss of
retinal function.
29–31 Given the potent neuroprotective effects of
o-3PUFAs
32 and their propensity to be incorporated into the
retina,
14 we sought to determine whether dietary supplementa-
tion with these lipids could delay the onset or decrease the severity
of retinal neuronal dysfunction in a mouse model of T2DM.
Male leptin-receptor deﬁcient (db/db) mice were maintained for
22 weeks (from 4 weeks to 26 weeks of life) on calorically and
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Nutrition and Diabetes (2012) 1–9 & 2012 Macmillan Publishers Limitedcompositionally matched diets, except for 2% enrichment in either
o-3 or o-6PUFAs. These rigorously deﬁned diets are identical,
except for fatty acids: 1% docosahexanoic acid and 1%
eicosapentanoic acid for o-3PUFAs or 2% arachidonic acid for
o-6PUFAs. Undeﬁned and variable ‘standard rodent chow’ varies
in its composition from batch to batch, depending on which oils
happen to be available to the manufacturer at the time of feed
production. For this reason, standard chow was only given to wild-
type control mice as a reference.
Nondiabetic heterozygote controls were maintained on normal
chow to assess baseline retinal function in healthy individuals. We
performed ERGs on db/db and control mice throughout the
progression of disease at 9, 14 and 26 weeks, and found that, in
contrast to o-6PUFAs, o-3PUFAs signiﬁcantly preserved retinal
function to levels akin to wild-type control mice receiving
standard chow (Figure 1a–d). With o-6PUFAs, we observed a
protracted loss in retinal function by 26 weeks of life compared
with both o-3PUFA-fed mice and age-matched control hetero-
zygotes on standard chow (gray line; Figure 1b–d). As shown in
Figure 1a, photoreceptor (a-wave) and postreceptor responses
(b-wave, OPs) were markedly attenuated. Saturating ERG response
amplitudes (Figure 1b) in the db/db mice (whether o-3- or
o-6PUFA-enriched) trended lower-than-normal at every test age
for the three mixed rod- and cone-mediated wavelets studied, P3
(RmP3), P2 (RmP2) and the OPs (Em
1/2). Indeed, age group 
wavelet ERG responses in the db/db mice were diminished
(Po0.0001); however, post-hoc testing detected no signiﬁcant
difference between the o-3PUFA db/db mice and the hetero-
zygous controls, whereas o-6PUFA db/db mice differed signiﬁ-
cantly from both. Post-hoc testing also revealed that P2 was more
attenuated than P3, consistent with synaptic compromise at the
outer plexiform layer. The effects of age (P¼0.009) and age 
group (P¼0.002) indicated that the magnitude of the functional
deﬁcit increased at 26 weeks only in the o-6PUFA db/db mice.
The amplitude of the cone-isolated response to 8Hz ﬂicker
(R8, Figure 1c) was also attenuated in the db/db mice (Po0.0001).
Again, effects of age (P¼0.009) and age group (P¼0.002)
indicated that the deﬁcit increased with age most severely in the
Figure 1. Omega-3 PUFA preserves retinal function in db/db mice. ERG assessment of db/db mice at 9, 14 and 26 weeks of age indicated that
o-3PUFAs preserve retinal function. (a) Selected from a dark-adapted ERG intensity series spanning a 2
30 range of stimuli, averaged responses
(lines) and one s.d. (ﬁlls) of 26-week-old mice maintained on o-6- and o-3PUFA-rich diets are shown; both increments are 2
8 after correcting for the
retina’s 50% lower sensitivity to the ‘white’ stimulus. The dim ﬂash (bottom) evoked a marked b-wave in the o3PUFA-fed mice, but no detectable
response in the o-6PUFA-fed mice. The moderate ﬂash (middle) evoked a pronounced a-wave in both the o-3- and o-6PUFA-fed mice, but did not
elicit a detectable post-receptor response (b-wave or OPs) in the ERG of the o-6PUFA-fed mice. The bright ﬂash (top) evoked a saturating a-wave in
both the o-3- and the o-6PUFA-fed mice. In the former, the a-wave was large, the OPs were pronounced and the b-wave rose well above baseline;
in the latter, the a-wave was smaller, and both the b-wave and the OPs were strikingly enervated. (b) Mean values of ERG parameters describing
the saturating amplitude of responses originating in photoreceptors, (RmP3, top), bipolar cells (RmP2, middle) and other postreceptor neurons (Em
1/
2, bottom) are plotted for the o-3 and o-6 db/db mice after normalizing by the values in age-matched heterozygotes on normal chow (grayed
data). These parameters were signiﬁcantly attenuated in o-6PUFA-fed, 26-week-old db/db mice. (c) The amplitude of the response to 8Hz ﬂicker
isolated to the cone pathway by a rod-suppressing adapting background (R8) is plotted as in b. R8 was somewhat reduced in db/db mice fed
o-3PUFAs-rich diets, but did not degenerate; db/db mice fed o-6PUFA-rich diets showed a severe decline (B1 log unit) in cone-pathway function
at age 26 weeks. (d) Retinal sensitivity at threshold (Sm), derived from P2, is plotted (again as in b). Sm was somewhat low in all db/db mice, but was
preserved by o-3PUFAs. In contrast, o-6-fed db/db mice suffered a profound loss of sensitivity (41.2 log units).
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isolated response than for the mixed rod/cone responses: B1 log
unit versus B0.6 log units. In addition, R8 in both the o-3 and o-6
db/db mice differed signiﬁcantly from the heterozygous controls.
Suprathreshold sensitivity parameters (S, kP2
 1) did not differ
between the o-3 and o-6PUFA db/db mice (data not shown).
However, retinal sensitivity at threshold (Sm, Figure 1d), which
depends on the function of both the photoreceptors and bipolar
cells, was low in the db/db mice (Po0.0001), especially in those
maintained on the o-6PUFA diet. Again, post-hoc testing, and
effects of age (P¼0.001) and age group (P¼0.01) revealed that
the loss in sensitivity in the o-3PUFA-fed mice was signiﬁcantly
less than in the o-6PUFA-fed mice.
These data indicate that o-3PUFAs effectively preserve retinal
function in T2DM. The average weight of o-3- and o-6PUFA-fed
mice did not vary signiﬁcantly in db/db mice or in control
heterozygotes (Supplementary Figure 1), although the db/db and
heterozygotes did differ from one another.
Omega-3-Rich diets enhance glucose homeostasis in db/db mice
Epidemiological studies show a lower incidence of T2DM in
individuals who consume higher levels of o-3PUFAs,
18 and
o-3PUFAs may enhance tolerance to systemic spikes in
glucose.
33,34 To evaluate the inﬂuence of o-3PUFA-rich diets
on glucose homeostasis, we ﬁrst measured fasting baseline
glycemia in db/db and heterozygous db/þ controls. Omega-
3PUFA-fed mice persistently demonstrated lower blood glucose
levels at 10 (P¼0.0087), 13 (P¼0.0203) and 16 (P¼0.0205) weeks;
(Figure 2a).
Glucose tolerance tests on mice of 7 weeks of age showed
improved glucose excretion from serum in o-3-fed db/db mice (at
30min) when compared with o-6PUFA-fed mice (P¼0.0379)
(Figure 2b). A similar beneﬁt was noted in heterozygous control
mice, with o-3PUFA-rich diets signiﬁcantly improving glucose
tolerance compared with normal chow (P¼0.0025; Figure 2c).
Thus, o-3PUFA-fed T2DM mice responded more normally to
spikes in glucose, suggesting that diets rich in o-3PUFAs confer a
protective systemic effect against the early manifestation of T2DM.
The protective effects of o-3PUFA-rich diets on retinal function are
independent of gross retinal cytoprotection
A primary manifestation of intermediate stage DR is the
degeneration of microvascular capillaries. Similar densities of
acellular capillaries were found in db/db mice on either diet
(P¼0.1973; Figures 3a–c), suggesting that the observed preserva-
tion in ERGs is independent of any o-3PUFA-mediated preserva-
tion of retinal vasculature integrity.
During progression of DR, there is speciﬁc loss of RGCs
5,6 in
humans
35,36 and animal models.
6,37,38 It is speculated that loss of
RGCs may precede the vascular manifestation of the disease. We
assessed if the heightened retinal function observed in o-3-fed
db/db mice was secondary to RGC neuroprotection. Equal
numbers of RGCs are present in o-3- and o-6PUFA-fed mice
(Figures 3d and e) in both central (P¼0.5538) and peripheral
(P¼0.8599) zones of the retina (Figure 3f). In line, the expression
of retinal bIII-tubulin mRNA remains constant, conﬁrming that RGC
numbers are equivalent in mice receiving either diet (P¼0.6698;
Figure 3g). Similarly, we did not detect any appreciable morpho-
logical differences in photoreceptors, or in the thickness of the
outer nuclear layer (Figures 3h–j). Consistent with these observa-
tions, the mRNA levels of cone opsin (Figure 3k) or rhodopsin
(Figure 3l)
39 did not signiﬁcantly vary between the feed groups,
suggesting similar photoreceptor numbers between the feed
groups. Taken together, these data suggest that the beneﬁt in
retinal function observed in o-3PUFA-fed db/db mice precedes
detectable anatomic changes in retinal vasculature and RGC
integrity, and may be independent of the vasoprotective effects of
o-3PUFAs.
The protective effects of o-3PUFA-rich diets on retinal function are
independent of inﬂammatory modulation
Given the anti-inﬂammatory effects of o-3PUFAs
40 and the role of
inﬂammation in DR, we determined the inﬂammatory status of the
Figure 2. Dietary o-3PUFAs improve glucose tolerance in db/db mice. (a) Fasting baseline blood glucose levels measured in o-3 and o-6PUFA-
fed db/db mice showed signiﬁcantly lower blood glucose levels at 10, 13 and 16 weeks in o-3PUFA-fed db/db mice (*Po0.05; **Po0.01; n¼14
per group). Baseline glycemia did not vary between the two feed groups in control nondiabetic heterozygotes db/þ mice. (b) Glucose
tolerance tests reveal o-3PUFA-fed db/db mice to be signiﬁcantly protected against glycemic spikes 30min after glucose injection (*Po0.05;
n¼5 per group). (c) A similar protective pattern by o-3PUFA feed was noted in nondiabetic heterozygote control mice. (*Po0.05, **Po0.01;
n¼5 per group).
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Representative images of retinal capillaries from o-3- (a)o ro-6PUFA-fed (b) db/db mice at 26 weeks of age reveal no statistically signiﬁcant change
in the number of acellular capillaries (white arrows) as quantiﬁed in (c). Representative images of b-III tubulin-stained RGCs from the peripheral (d)
and central regions (e)o fr e t i n a sf r o mo-3- and o-6PUFA-fed db/db mice at 26 weeks reveal no statistically signiﬁcant change in total numbers
between feed groups (f). (g) Real-time qPCR quantiﬁcation of b-III tubulin from whole retinas of 26-week-old db/db mice (normalized to millions of
copies of Cyclophilin A (cyclo) mRNA) conﬁrm comparable numbers of RGCs in both feeds; n¼7r e t i n a sf o ro-3PUFA and n¼5f o ro-6PUFA group.
Photoreceptor densities were unaffected by feeds. 4’,6-diamidino-2-phenylindole (DAPI)-stained retinas from o-3- (h)a n do-6-fed (i) db/db mice at 26
weeks of age revealed that photoreceptor densities were unaffected. Real-time qPCR quantiﬁcation of cone opsin (j) and rhodopsin (k)m R N A .
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corresponding to the time point of maximal measured
discrepancy in ERG signal between o-3- and o-6PUFA-fed db/db
mice, (Figure 1) all tested inﬂammatory cytokines, including IL-1b
(P¼0.7484; Figure 4a), IL-6 (P¼0.6163; Figure 4c), tumor necrosis
factor-a (P¼0.3456; Figure 4b), intercellular adhesion molecule-1
(P¼0.2976; Figure 4d) and the anti-inﬂammatory IL-10
(P¼0.4296; Figure 4e), showed similar retinal mRNA expression
levels in animals receiving either o-3- or o-6PUFA-rich diets.
We next assessed the expression of key constituents of vascular
barrier function. As with the proﬁles of inﬂammatory mediators,
retinal mRNA levels of the tight-junction protein claudin-5
(P¼0.3501; Figure 4f) and plasmalemma vesicle-associated
protein, an indicator of vessel permeability
41,42 (P¼0.7220;
Figure 4g) did not vary with feeds and neither did vascular
endothelial growth factor (P¼0.8449; Figure 4h). Similarly, protein
levels of the key inﬂammatory mediators did not vary with feed in
the serum of o-3- and o-6-fed mice: IL-1b (P¼0.9046; Figure 5a),
tumor necrosis factor-a (P¼0.7609; Figure 5b), IL-6 (P¼0.9362;
Figure 5c) and IL-10 (P¼0.8857; Figure 5d). Moreover, systemic
levels of VEGF remained unaffected by feed (P¼0.9576;
Figure 5e), as did the levels of insulin (P¼0.2020; Figure 5f).
Taken together, our data suggest that the protective effects of
o-3PUFAs on retinal function in T2DM occur independently of
inﬂammation, cell survival or barrier function, suggesting that o-3-
rich diets robustly protect neuronal function via a mechanism
independent of or preceding macrocellular changes.
DISCUSSION
The clinical diagnosis of DR presently relies entirely on the
detection of vascular lesions such as capillary degeneration, retinal
edema and hemorrhages (in early stages), or neovascular
Figure 4. Inﬂammation and permeability markers in db/db retinas do not vary with o-3 or o-6PUFA feeds. Real-time qPCR for inﬂammatory
cytokines at 26 weeks ((a) IL-1b,( b) tumor necrosis factor (TNF)-a,( c) IL-6, (d) intercellular adhesion molecule-1 and (e) the anti-inﬂammatory
cytokine IL-10) reveal no change in inﬂammatory proﬁles between feeds at this stage of the disease. Similarly, tight-junction protein
claudin-5 (Cln-5) (f), cell-permeability markers plasmalemma vesicle-associated protein (Plvap) (g), and permeability and angiogenic factor
vascular endothelial growth factor (VEGF) (h) do not vary with feed. All genes are normalized to copies of Cyclophilin A (cyclo A) mRNA;
n¼5 mice per group.
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presumption that the disease is exclusively microvascular in
nature and that effective treatments would have to either directly
counter stressors to the endothelium or alleviate the burden
of pro-angiogenic factors present in the vitreous. On the other
hand, T2DM is also characterized by a general metabolic
dysregulation and systemic dyslipidemia.
43 By directly modu-
lating dietary lipid consumption to favor o-3PUFA intake, we
efﬁciently stalled the deterioration of retinal visual function
associated with DR before any vasoprotective effects, and
independent of the anti-inﬂammatory properties of these lipids.
This suggests that o-3PUFAs have the capacity to protect cellular
function in DR and thus delay the early events of diabetes-induced
neuronal dysfunction in the retina. With a 2% change in fatty acid
content (o-3 vs o-6), there is a two-fold increase in retinal o-3
levels,
14 and this is also reﬂected in erythrocyte composition. It is
however important to note that the diabetic-like phenotype
observed in db/db mice results secondarily to dyslipidemia and
obesity, and therefore speciﬁc changes in lipid metabolism may
differ from that observed in human type 2 diabetes. Hence, it is
conceivable that lipid supplementation protocols could have
beneﬁcial effects in db/db mice that differ from human diabetic
patients.
Although the mechanisms assuring the functional protection
of the neural retina by o-3PUFAs presently remain elusive,
it is important to note that the observed beneﬁts were accom-
panied by enhanced glucose tolerance in o-3PUFA-fed mice.
Neurons require a steady supply of glucose and thus cannot
rely on glycolytic bursts nor depend on episodic insulin-driven
glucose uptake.
44 Consequently, neuronal glucose uptake is highly
dependent on the insulin-unresponsive GLUT-1,
45 and thus the
extracellular concentrations of glucose. Persistent hyper-
glycemia in diabetes can result in sustained levels of neuronal
glucose up to fourfold in healthy individuals and lead to glucose
neurotoxicity.
46 It is therefore tempting to speculate that the lower
systemic glycemia and signiﬁcantly improved ability to respond to
glucose challenge in o-3PUFA-fed animals may contribute, in part,
to the protective effects of o-3PUFAs on neuronal function. It is
noteworthy that there is a loss of weight in o-6PUFA-fed mice that
commences after 12 weeks of life (Supplementary Figure 1),
suggesting that animals on these diets thrive less than those on
o-3PUFA-rich diets.
Although we observed a beneﬁcial effect of o-3PUFA-rich diets
on the preservation of retinal function in T2DM, our study has
limitations. For example, retinal samples were collected and
analyzed subsequent to the ﬁnal ERG recordings at 26 weeks
Figure 5. Systemic markers of inﬂammation in serum of db/db mice do not vary with o-3 or o-6PUFA feeds. ELISA measurements performed
on serum at 26 weeks; ((a) IL-1b,( b) tumor necrosis factor (TNF)-a,( c) IL-6 and (d) the anti-inﬂammatory cytokine IL-10) reveal no change in
inﬂammatory proﬁles between feeds at this stage of the disease. Similarly, vascular endothelial growth factor (VEGF) levels (e) and insulin (f)
do not vary with feed; n¼5 mice per group.
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proﬁles occurred at an earlier time point, but normalized by 26
weeks of age. Conversely, it is also possible that gross changes in
retinal structure, such as capillary dropout and RGC loss, would be
detected at later time points than those sampled. However, we
carried out these analyses at a time corresponding to the greatest
discrepancy in retinal function between our treatment groups.
Although the functional protection afforded by the o-3-rich diets
did not show detectable cellular preservation, our study was not
designed to account for discrepancies in cell–cell interaction nor
for differences in retinal signaling.
Given that the current treatment modalities to counter DR are
costly, invasive and unproven for the long term, nutritional
interventions have the potential to result in a signiﬁcant
improvement over existing approaches in that the proposed
o-3PUFA lipid-based strategies are readily available, safe and
inexpensive, and also protect against macrovascular complications
of diabetes. Notably, o-3PUFA-rich diets have the potential to
prevent visual decline in the very early stages of DR before the
clinical manifestation of the disease.
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